The acquisition allows Sysmex to enter the cytogenetics market and strengthens its technology base in molecular genetics, while expanding its life science business.
Interviews with leading UK scientists revealed apprehension about losing access to European funding, limitations on freedom of movement, and an exodus of biotechs to the EU.
The genomic products and services firm said that no assets or personnel will be transferred, but it will license its analysis software to Source BioScience.
The company plans to launch a suite of small cancer panels initially for research, but it could eventually seek regulatory approval for them as diagnostics.
While there are already many companies in the space, Agilent believes its relatively quick protocol and higher-throughput capacity will set it apart from competitors' products.
